Monopar Therapeutics Inc.MNPRNASDAQ
LOADING
|||
R&D Expense Growth Accelerating
Trending higher, above historical average.
Left:
||||
Year-over-year research & development expense growth
Latest
132.24%
↑ 65% above average
Average (9y)
79.97%
Historical baseline
Range
High:233.62%
Low:-26.23%
Volatility
325.0%
High variability
| Period | Value |
|---|---|
| 2024 | 132.24% |
| 2023 | -26.23% |
| 2022 | 16.92% |
| 2021 | 59.73% |
| 2020 | 106.51% |
| 2019 | 10.96% |
| 2018 | 89.67% |
| 2017 | 233.62% |
| 2016 | 176.25% |
| 2015 | 0.00% |